Although it is evident that the CV protective effects of DPP-4 inhibition result from improving T2DM, a major risk factor for CV complications, accumulating evidence from experimental and clinical studies has suggested a direct effect of GLP-1 on the myocardium [21]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.